Annual Cash & Cash Equivalents
$7.58 M
-$3.87 M-33.82%
December 31, 2023
Summary
- As of February 7, 2025, ERNA annual cash & cash equivalents is $7.58 million, with the most recent change of -$3.87 million (-33.82%) on December 31, 2023.
- During the last 3 years, ERNA annual cash & cash equivalents has risen by +$5.95 million (+364.72%).
- ERNA annual cash & cash equivalents is now -55.40% below its all-time high of $16.98 million, reached on December 31, 2021.
Performance
ERNA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$4.26 M
+$1.68 M+64.89%
September 30, 2024
Summary
- As of February 7, 2025, ERNA quarterly cash and cash equivalents is $4.26 million, with the most recent change of +$1.68 million (+64.89%) on September 30, 2024.
- Over the past year, ERNA quarterly cash and cash equivalents has dropped by -$3.31 million (-43.71%).
- ERNA quarterly cash and cash equivalents is now -91.50% below its all-time high of $50.16 million, reached on June 1, 2021.
Performance
ERNA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ERNA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -33.8% | -43.7% |
| 3 y3 years | +364.7% | -21.0% |
| 5 y5 years | +364.7% | -21.0% |
ERNA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -55.4% | at low | -81.9% | +132.1% |
| 5 y | 5-year | -55.4% | +364.7% | -91.5% | +161.6% |
| alltime | all time | -55.4% | +364.7% | -91.5% | +161.6% |
Eterna Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $4.26 M(+64.9%) |
| Jun 2024 | - | $2.59 M(-49.5%) |
| Mar 2024 | - | $5.12 M(-32.5%) |
| Dec 2023 | $7.58 M(-33.8%) | $7.58 M(+66.4%) |
| Sep 2023 | - | $4.55 M(+147.7%) |
| Jun 2023 | - | $1.84 M(-66.0%) |
| Mar 2023 | - | $5.40 M(-52.8%) |
| Dec 2022 | $11.45 M | $11.45 M(-13.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $13.25 M(-31.7%) |
| Jun 2022 | - | $19.41 M(-17.4%) |
| Mar 2022 | - | $23.50 M(+38.4%) |
| Dec 2021 | $16.98 M(+942.0%) | - |
| Dec 2021 | - | $16.98 M(-30.3%) |
| Sep 2021 | - | $24.38 M(-51.4%) |
| Jun 2021 | - | $50.16 M(+496.5%) |
| Mar 2021 | - | $8.41 M(+415.9%) |
| Dec 2020 | $1.63 M | $1.63 M |
FAQ
- What is Eterna Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Eterna Therapeutics?
- What is Eterna Therapeutics annual cash & cash equivalents year-on-year change?
- What is Eterna Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Eterna Therapeutics?
- What is Eterna Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Eterna Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of ERNA is $7.58 M
What is the all time high annual cash & cash equivalents for Eterna Therapeutics?
Eterna Therapeutics all-time high annual cash & cash equivalents is $16.98 M
What is Eterna Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, ERNA annual cash & cash equivalents has changed by -$3.87 M (-33.82%)
What is Eterna Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ERNA is $4.26 M
What is the all time high quarterly cash and cash equivalents for Eterna Therapeutics?
Eterna Therapeutics all-time high quarterly cash and cash equivalents is $50.16 M
What is Eterna Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, ERNA quarterly cash and cash equivalents has changed by -$3.31 M (-43.71%)